The SLC22A8 antibody targets the solute carrier family 22 member 8 (SLC22A8), also known as organic anion transporter 3 (OAT3), a transmembrane protein primarily expressed in the kidneys, specifically in the basolateral membrane of proximal tubule cells. OAT3 facilitates the uptake of endogenous organic anions, such as urate, prostaglandins, and steroid conjugates, as well as exogenous drugs (e.g., antibiotics, antivirals, diuretics) from the bloodstream into renal cells for subsequent excretion. This transporter plays a critical role in maintaining systemic homeostasis by regulating the elimination of metabolic waste and xenobiotics. Research on SLC22A8/OAT3 has focused on its involvement in drug-drug interactions, nephrotoxicity, and diseases like hyperuricemia or chronic kidney disease. The SLC22A8 antibody is widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to study protein expression, localization, and regulation in renal tissues or cell models. Its application aids in understanding transporter function under physiological or pathological conditions, including polymorphisms or altered activity affecting drug pharmacokinetics. Validating antibody specificity is crucial due to potential cross-reactivity with other SLC22 family members. Studies utilizing this antibody contribute to advancing precision medicine and therapeutic strategies targeting renal transport pathways.